Free shipping on all orders over $ 500
Inhibitors
| Cat.No. | Name | Information |
|---|---|---|
| M9581 | AZD1390 | AZD1390 is a potent and selective inhibitor of ATM in cells (IC50 = 0.78 nM) with the ability to cross the blood-brain barrier. |
| M9128 | AZ31 | AZ31 is a potent and highly selective ATM inhibitor. |
| M8914 | AZD6738 | AZD6738 is an orally active, and selective ATR kinase inhibitor with IC50 of 1 nM. |
| M6080 | BAY-1895344 | Identification of potent, highly selective and orally available ATR inhibitor BAY 1895344 with favorable PK properties and promising efficacy in monotherapy and combination in preclinical tumor models |
| M5138 | Mirin | Mirin is a potent Mre11–Rad50–Nbs1 (MRN) complex inhibitor, and inhibits Mre11-associated exonuclease activity. |
| M3570 | Candesartan Cilexetil | Candesartan Cilexetil is a specific nonpeptide Ang II receptor (ATR) antagonist and the procompound of candesartan which is an ATR antagonist with an IC50 of 15 μg/kg. |
| M3115 | VE-822 | VE-822 is an ATR inhibitor with IC50 of 19 nM. |
| M2505 | CGK 733 | CGK 733 is a potent and selective inhibitor of ATM/ATR with IC50 of ~200 nM. |
| M2412 | AZ20 | AZ20 is a novel potent and selective inhibitor of ATR kinase with IC50 of 5 nM, 8-fold selectivity over mTOR. |
| M2309 | CP-466722 | CP-466722 is an potent and reversible ATM inhibitor. |
| M2187 | ETP-46464 | ETP-46464 is a potent inhibitor against mTOR, ATR, DNA-PK, PI 3-Kα and ATM with IC50 of 0.6, 14, 36, 170 and 545 nM, respectively. |
| M2047 | VE-821 | VE-821 is a highly selective and potent ATR inhibitor with IC50 of 26 nM. |
| M1998 | KU-60019 | KU-60019 is a potent ATM kinase inhibitor with IC50 of 6.3 nM. |
| M1801 | KU-55933 | KU-55933 is a cell-permeable ATP-competitive inhibitor of ATM (IC50 = 13 nM; Ki = 2.2 nM) with selectivity over other PIKK family kinases (IC50 = 2.5, 9.3, 16.6 μM for DNAPK, mTOR, PI 3-K, respectively; IC50 > 100 μM for PI 4-K and ATR). |
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2020 AbMole BioScience. All Rights Reserved.
